Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of Dengue Fever in Pakistan.

PloS one·2026
Same author

Emergence and genomic characterization of Listeria monocytogenes causing human listeriosis in Pakistan, 2017-2023.

BMC microbiology·2026
Same author

Identification and drug resistance profiling of <i>Mycobacterium orygis</i> from an African elephant using whole-genome sequencing.

Microbiology spectrum·2026
Same author

Correction: Spatio-temporal distribution of Crimean-Congo Hemorrhagic Fever and its relationship with climate factors in Pakistan: A decade-long experience from tertiary care laboratory network.

PloS one·2026
Same author

SQLE mutations and antifungal susceptibility profile of Trichophyton species isolated from patients with recalcitrant dermatophytosis: A laboratory-based study from Pakistan.

Medical mycology·2026
Same author

Risk Factors and Clinical Outcomes of Invasive Fungal Infections in Patients with Severe COVID-19: A Case-Control Study.

Pathogens (Basel, Switzerland)·2025
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Community-acquired pneumonia.

Muhammad Irfan1, Joveria Farooqi, Rumina Hasan

  • 1Department of Medicine, Aga Khan University, Karachi, Pakistan.

Current Opinion in Pulmonary Medicine
|February 21, 2013
PubMed
Summary
This summary is machine-generated.

New strategies improve community-acquired pneumonia (CAP) outcomes. Advances in risk stratification, biomarkers, diagnostics, and vaccines aid in reducing CAP burden, especially for the elderly. Further research is essential.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Related Experiment Videos

Last Updated: May 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Geriatrics

Background:

  • Community-acquired pneumonia (CAP) is a major cause of illness and death, particularly in older adults.
  • Aging global populations increase the number of individuals at risk for CAP.
  • Effective management and prevention strategies are crucial to mitigate CAP's impact.

Purpose of the Study:

  • To summarize recent advancements in managing and preventing community-acquired pneumonia (CAP).
  • To highlight emerging trends in risk stratification, diagnostics, and therapeutic approaches for CAP.
  • To emphasize the need for ongoing research in CAP prevention and treatment.

Main Methods:

  • Review of current literature on community-acquired pneumonia (CAP) management.
  • Analysis of emerging data on risk stratification indices and biomarkers.
  • Evaluation of new diagnostic tools and therapeutic guidelines.

Main Results:

  • Novel risk stratification tools show promise for predicting intensive care unit (ICU) admission.
  • Biomarkers like procalcitonin aid in assessing disease severity and guiding antibiotic use.
  • New diagnostics enable earlier and more targeted CAP therapy.
  • Coinfections are increasingly recognized; combination therapy is advised for severe CAP.
  • Pneumococcal conjugate vaccine (PCV13) approval offers enhanced prevention for at-risk adults.

Conclusions:

  • Despite progress, further research is needed to reduce CAP morbidity and mortality.
  • Adapting CAP prevention strategies to demographic shifts, like increased life expectancy, is essential.
  • Continued innovation in diagnostics, therapeutics, and vaccines is vital for combating CAP.